Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of HLX70 in Healthy Adult Volunteers
NCT04561076Phase 1Withdrawn
- Sponsor
- Hengenix Biotech
- Start
- Dec 2020
- Primary completion
- Sep 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
Phase 1, randomised, double-blind trial of HLX70 in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Hengenix Biotech. Primary endpoints: Number of participants with adverse events, serious adverse events and infusion-related reactions up to 92 days and Proportion of subjects undergoing Dose-Limiting Toxicity (DLT) events. Planned start Dec 2020; status: withdrawn.
02
Drugs
HLX70
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04561076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04561076.